Abstract: Hepatitis E virus (HEV) is the most common cause of viral hepatitis in the world. It is estimated that millions of people are infected every year, resulting in tens of thousands of deaths. However, these estimates do not include industrialized regions and are based on studies which employ assays now known to have inferior sensitivity. As such, this is likely to represent a massive underestimate of the true global burden of disease. In the developing world, HEV causes large outbreaks and presents a significant public-health problem. Until recently HEV was thought to be uncommon in industrialized countries, and of little relevance to clinicians in these settings. We now know that this is incorrect, and that HEV is actually very common in developed regions. HEV has proved difficult to study in vitro, with reliable models only recently becoming available. Our understanding of the lifecycle of HEV is therefore incomplete. Routes of transmission vary by genotype and location: endemic regions experience large waterborne epidemics, while sporadic cases in industrialized regions are zoonotic infections likely spread via the food chain. Both acute and chronic infection has been observed, and a wide range of extrahepatic manifestations have been reported. This includes neurological, haematological and renal conditions. As the complete clinical phenotype of HEV infection is yet to be characterized, a large proportion of cases go unrecognized or misdiagnosed. In many cases HEV infection does not feature in the differential diagnosis due to a lack of knowledge and awareness of the disease amongst clinicians. In combination, these factors have contributed to an underestimation of the threat posed by HEV. Improvements are required in terms of recognition and diagnosis of HEV infection if we are to understand the natural history of the disease, improve management and reduce the burden of disease around the world.
Introduction
The existence of an epidemic, non-A, non-B hepatitis unrelated to blood transfusion was first recognized in India in the late 1970s. 1 Subsequently, a Soviet scientist investigating outbreaks of unexplained non-A, non-B hepatitis amongst troops in Afghanistan ingested a pooled stool sample from affected soldiers. He developed an acute hepatitis, and a novel virus was identified in his faeces by electron microscopy. 2 Almost a decade later, the viral genome of the newly named hepatitis E virus (HEV) was successfully sequenced. 3, 4 HEV is now recognized as the most common cause of acute viral hepatitis worldwide. There are an estimated 20 million infections per year, resulting in 3 million symptomatic cases and around 70,000 HEV-related deaths. [5] [6] [7] As large as these figures are, this is likely to represent a gross underestimate of the true global burden of disease. 8 In resource-poor countries HEV represents a significant health issue, causing both sporadic cases and large outbreaks affecting thousands of people. 9 Several large-scale epidemics of acute viral hepatitis in southern Asia, which were previously considered to be epidemics Hepatitis E: an underestimated emerging threat of hepatitis A, have since been retrospectively identified as hepatitis E. 1, 10 Seroprevalence studies suggest that as much as one third of the world's population will be infected at some point during their lifetime. 11 In endemic regions the case-toinfection ratio is between 1:3 and 1:4 12, 13 ; taken together, these figures indicate that in excess of half a billion people have had clinically apparent hepatitis E. 11 Despite this, the clinical phenotype of HEV infection remains incompletely characterized, and the majority of infections are unrecognized or misdiagnosed. How can we have got it so wrong for so long? There are a number of reasons. In developed nations, the received wisdom for many years was that hepatitis E was clinically indistinguishable from hepatitis A and restricted to travellers returning from endemic areas. 14 This view was reinforced by successive generations of serology assays which were not fit for purpose, leading to missed diagnoses and underestimates of levels of seroprevalence. 15 As such, HEV was considered of little relevance to clinicians in industrialized countries. This is now known to be incorrect, and locally acquired cases of HEV infections have been reported in nearly all European countries, [16] [17] [18] North America, 19 Australasia 20,21 and Japan. 22, 23 Until recently there were no efficient cell-culture models available, 24,25 which limited progress in elucidating the lifecycle and characteristics of HEV. The range of clinical presentations, epidemiological patterns and routes of transmission vary widely by genotype, host characteristics, geographical location and over time. Taken together, these factors present significant challenges to understanding and appreciating the threat posed by HEV to human health.
Virology of HEV
HEV is a member of the Orthohepevirus genus, which itself is part of the Hepeviridae family. Orthohepevirus contains four species (A to D), 26 with human disease being caused by strains of species A. There are eight genotypes of species A. 27 Two of these are obligate human pathogens (HEV1, HEV2), and two are endemic in several animal species, causing zoonotic infections in humans (HEV3, HEV4). The remaining genotypes appear to be restricted to wild boar (HEV5, HEV6) and camels (HEV7, HEV8), although a case of human HEV7 infection has been reported. 28 HEV is an icosahedral, positive-strand RNA virus with a 7.2kb genome which contains three open reading frames (ORFs). 29 These ORFs are translated into proteins responsible for RNA replication (ORF1), the viral capsid (ORF2) and viral particle secretion (ORF3). 29 While ORF2 is the most wellstudied of the HEV proteins, given its role as an antigen, the less well characterized ORF3 protein may play a key role in how HEV interacts with the host's immune response. 29 HEV has always been considered to be a nonenveloped virus. This was based on the appearance of virions isolated from faeces, which are naked. The same is true of virions found in bile. However, virions found in blood are wrapped in host-cell membranes. 30 The process by which HEV particles become enveloped is not fully understood, but ORF3 appears to play a key role. 31 It has been suggested that the detergent action of bile may degrade the envelope of HEV virions, resulting in the nonenveloped particles observed in bile and faeces. 32 The quasi-enveloped HEV virions do not have any antigenic proteins on their surfaces, and as such are resistant to the neutralizing effects of anti-ORF2 antibodies. 31 Interestingly, HEV isolated from serum is less infectious than that derived from faeces, 33,34 and quasi-enveloped and nonenveloped virions have separate mechanisms for entering host cells. 35 By adopting these two distinct forms, HEV is able both to evade an existing host's immune response and maximize infectivity of new hosts.
In addition to providing protection against the host immune response, the quasi-envelope may also grant HEV access to otherwise inaccessible areas. A wide range of extrahepatic manifestations of HEV infection have been described, 36 and HEV is able to replicate in human neuronal and placental-derived cell lines. 37, 38 It has been suggested that the quasi-envelope may lend HEV exosome-like properties, 39 which allow it to enter a range of cell types via an endocytic mechanism. 32 These similarities to exosomes may also allow quasi-enveloped HEV to enter immunologically privileged sites, including the central nervous system 40 and the testes. 41 
Clinical picture of HEV infection

Acute infection
There is substantial heterogeneity in the clinical presentation of HEV infection both between and within developing and developed countries. In journals.sagepub.com/home/tai 3 resource-poor settings the majority of cases, both sporadic and epidemic, involve either HEV1 (Asia) or HEV2 (Africa and Central America 9 ). Young adults are most commonly affected, especially the 15-35 age group, and men are more likely to be infected than women. 42, 43 Most patients experience an acute, self-limiting hepatitis. Chronic infection with HEV1 or HEV2 is yet to be reported. The overall mortality rate ranges from 0.2% to 4%, 9 but this can be significantly higher in at-risk groups, such as those with pre-existing liver disease 44 and very young children. 45, 46 Pregnant women in developing countries are particularly vulnerable, with mortality as high as 25%, 47, 48 with preterm delivery in 66% of cases. 48 HEV-related deaths in pregnancy typically occur in the third trimester and are most often caused by fulminant hepatic failure or obstetric complications. 48 The mechanisms which underlie this excess mortality and increase in prematurity and pregnancy loss are not currently understood.
In developed countries, locally acquired infections are most commonly caused by HEV3, with HEV4 largely confined to Japan and China. 8 Acute infection in these areas produces a wide variety of clinical presentations. Only a small minority of patients, probably less than 5%, present with a typical picture of acute viral hepatitis. Despite this, HEV is the major cause of acute viral hepatitis in several European countries; in France, Germany and the UK during 2014 and 2015, there were more reported cases of acute hepatitis E than hepatitis A or acute hepatitis B. 49 Older men are predominantly affected, with a male to female ratio of around 3:1 and a median age around 63 years. 17 It is thought that this is due to host factors rather than any difference in exposure, with pre-existing subclinical liver disease suggested as a possible risk factor. An English study found an overrepresentation of excess alcohol consumption and diabetes amongst individuals with acute hepatitis E, both of which are risk factors for hepatic fibrosis and steatosis. 50 Generally, those that do present with clinically apparent hepatitis will experience an acute, self-limiting illness that lasts between 4 weeks and 6 weeks. 16 Progression to acute liver failure is rare, but a small number of individual cases have been reported in Europe, and a single-centre German study of 80 patients with acute liver failure found that HEV was the most likely cause in around 10% of cases. 51 Patients with pre-existing liver disease are at risk of acute-on-chronic liver failure; elderly patients are especially at risk. HEV is a less common cause of decompensation in developed countries 52, 53 than it is in resource-poor settings, perhaps reflecting differences in the pathogenicity of the dominant genotypes in different regions. 54 Somewhere between half 62 and two-thirds 61 of solid-organ transplant recipients who are exposed to HEV will develop a chronic infection. In patients infected with HEV3, rapid progression of liver fibrosis to cirrhosis, decompensation and death has been described. [55] [56] [57] 63 In solid-organ transplant recipients, risk factors for developing a chronic infection include a greater degree of immunosuppression and tacrolimus treatment. 61 In HIVpositive patients, chronic co-infection is uncommon, and seen only in individuals with a very low CD4+ count (< 200 cells/mm 3 ). 59 Factors predictive of chronic infection in other immunosuppressed groups are yet to be identified.
Chronic infection
Extrahepatic manifestations
Extrahepatic manifestations of HEV infection have been reported in both acute and chronic cases. A wide range of disparate conditions have been linked to HEV, including glomerulonephritis, haematological disorders, pancreatitis and autoimmune conditions including HenochSchönlein purpura, 64 thyroiditis 65 and myasthenia gravis. 66 However, by far the most commonly reported extrahepatic complications of HEV infection are neurological conditions. 67 
HEV and neurological injury
Around 150 cases of HEV-associated neurological injury have been described. 67 These cases are mostly from Europe, and involve HEV3, although HEV1-associated neurological injury has been reported in Asia. 68 The majority of cases involve immunocompetent patients, but there have been reports of neurological injury in chronically infected individuals. In all cases, the neurological signs and symptoms dominate the presentation. The patients' LFTs are usually only mildly or moderately deranged and they are typically anicteric. A proportion of patients have entirely normal LFTs. The range of neurological conditions which have been linked to HEV includes mononeuritis multiplex, Bell's palsy, vestibular neuritis, myositis and peripheral neuropathy. However, the best characterized HEV-associated neurological illnesses are Guillain-Barré syndrome (GBS), neuralgic amyotrophy (NA) and encephalitis/ myelitis. 67 GBS is an immune-mediated polyradiculopathy characterized by rapid onset, progressive muscle weakness which can cause respiratory compromise and autonomic dysfunction. 69 Approximately two-thirds of patients have a preceding infective illness; most commonly this is Campylobacter jejuni gastroenteritis, accounting for approximately 30% of cases. 69 However, in more than half of cases the preceding infection is not identified. 70 The first description of a HEV-associated neurological disorder was a case of GBS in India, which was reported in 2000. 71 However, 4 years prior to this a Dutch longitudinal study demonstrated that 30% of patients with GBS had moderately elevated LFTs at presentation, with no identifiable explanation for this derangement. 72 In addition to a growing number of case reports, 36 there have been three case-control studies examining the association between HEV infection and GBS. A Dutch study found that 5% of 201 patients with GBS had evidence of HEV infection at presentation, compared with 0.5% of controls (p = 0.026 73 ). HEV3 RNA was isolated from the stool or serum of three patients. Another study, from Bangladesh, found that 11/100 patients with GBS were infected with HEV. 68 The only case to be genotyped in this study involved HEV1. 68 A third case-control study, conducted in Japan, found that 4.8% of 63 patients with GBS were anti-HEV IgM positive during the acute phase of their illness. 74 None of the control subjects had evidence of acute HEV infection. 74 More recently, a Belgian cohort study found that 8% of patients with GBS had evidence of HEV infection. 75 The clinical picture of HEV-associated GBS is indistinguishable from cases not associated with HEV.
NA, also known as brachial neuritis or ParsonageTurner syndrome, is an acute monophasic neurological injury affecting the brachial plexus. 76 The aetiology of this condition is not fully understood, but in common with GBS it is thought to have a postinfectious, immune-mediated component. 76 The typical presentation involves sudden onset, unilateral pain in the dominant upper limb or shoulder, followed by progressive weakness and sensory impairment in the affected limb. 76 There have been a number of cohort and case studies of HEV-associated NA, virtually all from Europe and involving HEV3. In an Anglo-Dutch cohort study, 10.6% (5/47) of patients with NA were infected with HEV at the onset of their neurological symptoms. 77 An international, multicentre study of 118 European patients with NA identified a characteristic phenotype of HEV-associated disease compared with other patients with NA. 78 In HEV-associated cases symptoms tend to be more severe. Bilateral brachial plexus involvement is significantly more likely, and the damage tends to be more extensive. 78 There is also an increased risk of neurological injury outside the brachial plexus, most notably involving the phrenic nerve. 78 Another recent study, which prospectively tested consecutive patients with acute, nontraumatic neurological injury, found evidence of HEV infection in 2.4% of subjects (n = 464); three of these patients had NA, and all of them presented with the characteristic HEV-associated phenotype. 79 The association between HEV and this phenotype is so strong that in one UK centre, the combination of a middle-aged man presenting with bilateral shoulder pain and deranged LFTs is regarded as acute HEV infection until proven otherwise.
A total of 12 cases of HEV-associated encephalitis/ myelitis have been described in individual reports and small case series. Seven were from Europe, [80] [81] [82] [83] [84] [85] four were from Asia 86-89 and one was from the USA. 90 Five of these cases involved chronically infected solid-organ transplant patients. 80, 81 Five patients developed ataxic symptoms, and these patients tended to have poorer outcomes: two patients died, and those who survived had more significant long-term neurological sequelae. 81, 84, 85, 90 Six patients had HEV RNA in their serum and cerebrospinal fluid (CSF) at the onset of their illness. [80] [81] [82] 84, 85, 90 In one case, the HEV RNA found in the CSF differed significantly from that found in the serum. 80 This quasispecies compartmentalization may suggest the emergence of directly neurotropic strains of HEV. 80 HEV and renal injury HEV-associated glomerular disease has been reported in both immunocompetent and immunosuppressed patients. [91] [92] [93] [94] All but one case 91 have involved HEV3. A French study examined renal function and histology in a cohort of 51 solid-organ transplant recipients infected with HEV. 95 Renal function was significantly impaired in both the acute and chronic phases of infection. Renal biopsies were performed on patients with concomitantly increased proteinuria, and these showed features of membranoproliferative glomerulonephritis, IgA nephropathy and nephroangiosclerosis. Most patients also had cryoglobulinaemia. These effects all appear to be related to HEV infection. Other causes of renal impairment were excluded and viral clearance resulted in improved estimated glomerular filtration rate, reduced proteinuria and resolution of cryoglobulinaemia.
The mechanisms which underlie HEV-associated renal injury remain unclear. Cryoglobulinaemiaassociated glomerulonephritis is a well-recognized complication of hepatitis C virus (HCV) infection, and HEV may cause renal impairment in a similar way. As mentioned previously, cryoglobulinaemia appears to be common in HEVassociated renal disease. Notably, HEV RNA was isolated from the cryoprecipitate of one patient with HEV-associated glomerulonephritis. 94 
HEV and haematological disorders
Thrombocytopaenia has been reported in the context of both HEV1 and HEV3 infection. A UK study found that 12/106 patients infected with HEV presented with a low platelet count. Only three of these patients have platelet counts below 100 × 10 9 /L, and there were no significant clinical consequences. Nine cases of more severe thrombocytopaenia have been reported, 91,96-101 with a median platelet count of 10 × 10 9 /L. All of these patients had elevated alanine transaminase levels (median: 1045 IU/L). Platelet-associated antibodies were detected in two patients, 98 and it has been suggested that HEV may induce thrombocytopaenia via an immune-mediated mechanism 61 similar to that seen with HCV infection. 102 A number of other haematological conditions have been reported in association with HEV infection, mostly as single case reports. This includes autoimmune haemolytic anaemia 103 aplastic anaemia 104 and pure red-cell aplasia. 105 One UK study reported monoclonal gammopathy of uncertain significance (MGUS) in over 25% of patients infected with HEV; 106 prevalence in the general population is around 3%. 107 The significance of this observation is yet to be determined, but MGUS is associated with an increased risk of progression to multiple myeloma. 108
Diagnosis of HEV
The varied clinical phenotype of HEV infection makes diagnosis challenging, and this difficulty is compounded by number of other factors. Still regarded as an 'emerging' disease, knowledge of the condition is still limited amongst clinicians and as a result it can often be overlooked in the differential diagnosis of LFT derangement (Table  1) . Even amongst specialists HEV infection can be easily confused for other hepatobiliary conditions. Studies have shown that a significant proportion of patients diagnosed with drug-induced liver injury (DILI) in fact have acute hepatitis E. 109, 110 There is substantial overlap in the main demographic for hepatitis E, polypharmacy and DILI so it is easy to make this misdiagnosis if HEV infection is not considered. Similarly, it can be challenging to distinguish acute hepatitis E from autoimmune hepatitis, which commonly presents in older people, and can also produce false positive HEV serology tests due to nonspecific, cross-reactive antibodies. When a diagnosis of HEV infection is considered, there may not be a reliable test available. In the USA, there is no diagnostic assay approved by the US Food and Drug Administration. Elsewhere, some of the assays which are available have questionable sensitivity and specificity, while others can be limited by the natural history of HEV infection.
HEV has an incubation period of between 2 weeks and 8 weeks. During this time viraemia reaches its peak, before sharply declining. In acute infection HEV RNA becomes undetectable around 3 weeks after clinical symptoms appear, with the virus continuing to be shed in the stool for another 1-2 weeks. 111, 112 The initial immune response involves a rise in anti-HEV IgM, which remains detectable for 3-12 months. 113 This is superseded by a more sustained IgG response, which peaks around 4 weeks later than IgM and remains detectable for more than 1 year 113 ( Figure 1 ).
The assays that are available to diagnose HEV infection do so either indirectly or directly. Serological assays indirectly detect infection via the host immune response, and can help characterize the phase of HEV infection. Wide variation in the sensitivity and specificity of commercially available serological assays exists, 114 and the previous 'gold standard' test substantially underestimated seroprevalence in comparison to newer assays. 15 Also, in chronically infected, immunocompromised patients anti-HEV antibodies are often undetectable. Molecular analysis can be used to directly detect HEV RNA in blood or stool. These techniques offer a more reliable diagnostic assay, but have obvious limitations in terms of cost. In addition, as outlined previously, in cases of acute infection the viraemic window can be very narrow. Taken together, these diagnostic hurdles not only impair the clinical care of individual patients, but also impact our understanding of the significance, prevalence, transmission and epidemiology of HEV.
Routes of transmission and epidemiology of HEV HEV1 and HEV2 are both restricted to humans and are primarily spread faecal-orally via contaminated water. In hyperendemic regions with poor sanitation there are regular, large-scale epidemics resulting in significant morbidity and mortality. This includes most of southern Asia, 116-118 parts of Africa, 119 rural areas of China, particularly the remote Xinjiang region, 42, 120 and several Latin American countries. 121 However, outbreaks do not occur year on year in the same geographical region. Instead they appear periodically, despite the perennial presence of faecal contamination in the water supply. It has been suggested that this pattern is the result of a cohort effect. 122 Anti-HEV IgG seropositivity increases by as much as five times following an epidemic. Over the following years there is a decline in IgG seroprevalence, until it reaches a critical level where it no longer offers herd immunity and another epidemic occurs. 122 Direct person-to-person transmission via the faecal-oral route has been suggested as an additional factor contributing to both epidemic and sporadic cases of HEV. A large outbreak in Uganda in 2007-2008 has been proposed as an example of an epidemic spread via this route of transmission. 123, 124 The prolonged epidemic curve, high secondary attack rate within households and lack of an identified common source of infection were identified as evidence of person-to-person transmission. 123 Parenteral transmission of HEV via blood products has been reported in several countries. [125] [126] [127] [128] [129] [130] [131] In line with this, numerous studies have found healthy blood donors to be viraemic at the time of donation. 126, [132] [133] [134] [135] [136] [137] [138] [139] The rates of viraemia amongst blood donors vary widely from country to country, ranging from 1:27 in India 126 to 1:74,131 in Australia. 138 A Canadian study did not find any evidence of viraemia in nearly 14,000 blood donors. 140 The extent to which transfusion-related HEV infections contribute to the overall burden of disease is unclear. 141 However, many of the patients who are most likely to receive blood products are also those at most risk of chronic infection or severe acute hepatitis E. This includes pregnant women, with liver disease, transplant recipients and other immunosuppressed patients. In view of this, several European countries, including UK, Ireland, the Netherlands and Switzerland, now routinely screen donated blood for HEV. 142 The routes of transmission which are particular to industrialized regions add a further layer of complexity. Both HEV3 and HEV4 are zoonotic infections. The primary host species is thought to be pigs, 143 but the virus has been found in a range of mammalian species including wild boar, 144 deer 145 and rabbits. 146 Prevalence of antibodies to HEV exceeds 90% in UK pigs, and around 20% have evidence of active infection at the time of slaughter. 147 The virus is apathogenic in pigs, 148 making identification of infected animals difficult. It is thought that consumption of infected meat is the most important vector for HEV3 and HEV4, and the virus has been isolated from pork products at the point of sale. 149 Other food stuffs such as shellfish 150 and arable crops [151] [152] [153] have also been implicated.
The evidence suggests that locally acquired HEV infection is actually very common in richer nations; seroprevalence data and studies of blood donors suggest that at least two million individuals are infected in Europe each year. 8 The incidence of HEV infection has been observed to vary both between and within countries, and also changes over time. It is not currently understood why this is the case. In France the overall incidence is higher than in many other European countries, but is not uniformly distributed throughout the country. The incidence in France ranges from 0.4% to 4.6%, with the highest rates found in the southwest and southeast, to the extent that these regions are considered hyperendemic. 154 There are other hotspots of HEV infection throughout the continent, including the Netherlands, 155 western Germany, 156 Czech Republic, 49 western/central Poland 157 and central Italy. 158 In some European countries there has been a decline in HEV seroprevalence, suggesting a cohort effect where the incidence of infection was highest in the mid-20th century but has since been in decline. 159, 160 At the same time, the number of laboratory-confirmed cases has increased significantly across the continent. 49 This to some degree reflects improvements in case ascertainment as awareness of HEV is raised, but that is not the whole story. There have also been substantial increases in incidence in several countries. For example, in Scotland the number of viraemic blood donors has risen from 1:14,500 135 to 1:2481 161 in the space of 5 years. Over the same period there has also been a shift in the source of human HEV infection in Scotland. In the past the strains of HEV identified in humans in Scotland shared sequence homology with the strain found in local pig herds. More recent infections, by contrast, have been found to involve HEV strains more closely related to those found in pigs from continental Europe. The obvious implication of this is that there has been some change leading to an increased amount of contaminated pork products entering the UK food chain from Europe. 162 
Treatment
The majority of cases of acute HEV infection do not require any specific treatment. However, a subset of patients may progress to hepatic failure or develop serious extrahepatic sequelae. This raises the question of whether disease progression can be prevented, or ameliorated, with antiviral therapy. In both hepatitis B and C early treatment with antivirals has been shown to improve the natural history of the condition and produce more favourable outcomes. [163] [164] [165] A small number of patients with hepatitis E in both Europe and Asia have been treated with ribavirin. [166] [167] [168] [169] Following treatment liver enzyme levels quickly returned to normal and viral clearance was achieved. However, these results must be interpreted with caution due to the lack of controls and the substantial heterogeneity in the treatment regimens employed.
In the context of immunosuppression following solid-organ transplant, the first-line treatment of chronic HEV infection should be a reduction of immunosuppressive drugs, particularly those which target T cells. 61, 63 Ideally, this should be done as soon after diagnosis as is practicable; this will lead to viral clearance in around 33% of patients. 63 For patients who still have active HEV replication after 3 months, ribavirin may be of benefit ( Figure 2) . A cohort of 59 French solid-organ transplant recipients with chronic hepatitis E was treated with ribavirin. 170 The duration of treatment ranged between 1 month and 18 months; 66% of patients were treated for less than 3 months. HEV clearance was achieved in 95% of cases, and 78% had a sustained virologic response (SVR). Four patients who relapsed achieved SVR after a further period of treatment. 169 Ribavirin is effective against a wide range of RNA viruses. As such, several antiviral mechanisms have been proposed, one of which is lethal mutagenesis. 171 RNA virus intra-host populations have high levels of variation due to rapid RNA replication and the lack of proof-reading capability in RNAdependent RNA polymerase. 172 This means that these viruses run close to the genomic error threshold, the point at which the burden of mutation is incompatible with transmission of the virus' master sequence. 173 Ribavirin is incorporated into newly synthesized viral RNA, introducing mutations. 171 By increasing the error rate, ribavirin pushes the virus over this threshold and induces extinction. 173 Ribavirin has been observed to exert this effect on HEV. [174] [175] [176] [177] Higher rates of mutation increase the likelihood of acquiring mutations associated with the development of hepatic failure, progression to chronic infection and reduced immunoreactivity. 178 Mutations which confer resistance to ribavirin have also been reported. [174] [175] [176] [177] It has been suggested that selection of such variants which increase viral fitness may explain the treatment failure seen in some patients. 172 Pegylated interferon-α (IFNα) has been used to good effect in a small number of chronically infected liver transplant recipients, 179, 180 and one haemodialysis patient. 181 In general IFNα is not recommended in patients who have received transplants however, because the risk of acute rejection is increased. In other immunocompromised patients, this is not an issue. A handful of case reports and small case series have described effective treatment with IFNα, ribavirin and a combination of the two in patients with haematological malignancies [182] [183] [184] being treated with chemotherapy and HIV-positive patients. 82, 185, 186 
Prevention
In endemic regions where most infections are waterborne the primary prevention strategy involves improving sanitation and drinking water facilities. 187, 188 It has been shown that failure to take action to sterilize drinking water during epidemics is associated with larger scale outbreaks. 189 In areas where zoonotic transmission is predominant infection can be prevented by ensuring proper preparation of food products. Meat products, particularly pork and game, should be cooked thoroughly. 190, 191 At-risk individuals, such as pregnant women, those with pre-existing liver disease and immunosuppressed individuals should take particular care and avoid uncooked meat. Individuals who work with pigs, wild boar, game and their products should take steps to minimize direct contact and use protective equipment. 192 A highly effective vaccine has been commercially available in China for almost 6 years. 193 This vaccine has been designed to offer long-term protection against all HEV genotypes. 194 However, it is not yet licensed for use in the rest of the world, pending phase IV trials to determine its safety in children, the elderly, immunosuppressed patients and individuals with pre-existing liver disease. 195 
Research questions
There are many remaining questions regarding HEV.
( One interesting possibility is the issue of whether HEV3 and HEV4 could have an adverse outcome in pregnancy. Vertical transmission from an infected mother to the foetus is an important route of HEV infection in Asia and Africa. Mother-tochild transmission rates in excess of 75% have been reported, leading to substantial foetal and perinatal morbidity and mortality. 196, 197 Thus far, this route of transmission has only been associated with HEV1 and HEV2; no cases have been reported with HEV3 or HEV4. 198 However, a recent in vitro study demonstrated that HEV3 can replicate on placenta-derived human cell lines. 37 In addition, rabbit HEV (rHEV), which is closely related to HEV3, 199 has been linked to increased rates of stillbirth and miscarriage amongst experimentally infected animals. 200 It has also been demonstrated that rHEV can be transmitted vertically. 201 While no cases of vertically transmitted HEV3 have been reported, the possibility cannot be excluded. At present, the causes of miscarriage are often unknown, but infections are implicated in up to 15% of early miscarriages (< 12 weeks) and 66% of late miscarriages (12-24 weeks 202 ). Subclinical and occult infections are similarly thought to play an important role in both spontaneous preterm labour and preterm premature rupture of the membranes. 203 Importantly, up to 25% of stillbirths are unexplained by current investigations. 204 As mentioned previously, HEV infection is often subclinical or presents atypically, and the seroprevalence in many developed nations is much higher than was previously thought. 114 The role of HEV infection in adverse pregnancy outcomes warrants further study.
Conclusion
It is increasingly clear that we have been slow to recognize the threat posed by HEV. A range of factors have contributed to this. Unreliable assays have led to both misdiagnosis and underestimates of disease burden, particularly in developed nations. As a result there is a lack of awareness, knowledge and recognition of this disease amongst clinicians. We still do not fully understand the lifecycle of the virus, not least because of the longstanding difficulties experienced in developing a reliable in vitro model. The substantial heterogeneity in clinical presentation between geographical locations, genotypes and host demographic groups pose significant challenges both in terms of diagnosis and in understanding the natural history of the disease. Similarly, the complex web of transmission routes and variation in incidence and prevalence in different regions and over time makes understanding the epidemiology of HEV extremely difficult.
It is vital that we continue to improve recognition and diagnosis of HEV, by increasing both awareness and knowledge of the disease amongst clinicians. In order to achieve this we must continue to elucidate the clinical phenotype of HEV infection, particularly the myriad extrahepatic manifestations with which it has been linked. Similarly, we must improve our understanding of how HEV is transmitted, especially the zoonotic strains primarily seen in developed countries. Only then will we be able to fully appreciate the emerging challenge of HEV.
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